Day: February 21, 2025

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 20 02 2025] – (CGWL)

Written by Customer Service on February 21, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Havila Kystruten AS: Invitation to Q4 2024 Earnings Call Presentation

Written by Customer Service on February 21, 2025. Posted in Public Companies.

Havila Kystruten AS will publish its Q4 2024 financial report on Thursday, February 27, 2025. Bent Martini, CEO, and Aleksander Røynesdal, CFO, will present the results in an earnings call at 10:00 CET on Friday, February 28, 2025, followed by a Q&A session. The earnings call can be accessed through the following link: Link to the external registration page A recording will be available on the Company’s website. Contacts: Chief Executive Officer: Bent Martini, +47 905 99 650 Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114

Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights

Written by Customer Service on February 21, 2025. Posted in Public Companies.

Physician caring for patientNurse caring for patientSystem ArchitectureFebruary 21, 2025 Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Mass General Brigham (MGB), home to one of the largest hospital system-based research enterprises in the US, today announced a new collaboration to develop and deploy advanced data infrastructure and AI designed to integrate and process live healthcare data from a wide range of sources to improve patient care. Today, healthcare providers often rely on disparate data sources, including static Electronic Medical Record (EMR) data, clinical notes, and isolated device alarms. By streaming accurate, reliable and detailed...

SSCP Lager Bidco AB (publ) – Interim report for fourth quarter 2024

Written by Customer Service on February 21, 2025. Posted in Earnings Releases And Operating Results.

Date: 21st of February 2025SSCP Lager BidCo AB (publ) – Interim report for the period 1 October – 31 December 2024. Today SSCP Lager Bidco AB (publ) published the interim report for the fourth quarter, the report can be downloaded on www.logent.se or via the link below. For more information, please contact:Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se or Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se This press release was published on 21stof February at CET 09:00 This information is information that SSCP Lager BidCo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 21-02-2025 at 09:00 CET. About Logent GroupLogent is a comprehensive and...

Cabka N.V. Announces 2024 Preliminary Update: resilient portfolio growth and margin expansion in challenging markets

Written by Customer Service on February 21, 2025. Posted in Earnings Releases And Operating Results.

Amsterdam February 21, 2025 – Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, announced its 2024 preliminary update today. Cabka expects full year 2024 sales to be around €182 million, in line with the guided range of €180 – €185 million. In Europe, our Portfolio business grew by 8% year-over-year, including intentional price reductions of approx. 4%. The customized solutions business in Europe remained relatively resilient to market conditions. Our US Portfolio business grew by 10% in 2024, reflecting our successful commercial strategy and regaining market share, which was made possible through the strengthening of our sales force in the region. The ECO...

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting

Written by Customer Service on February 21, 2025. Posted in Public Companies.

Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders’ general meeting convened for March 10, 2025Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025. Preliminary results of the Repurchase As announced on February 10, 2025 and February 14, 2025, GENFIT has proposed to all of the 2025 OCEANEs holders to enter into a Put Option Agreement, pursuant to which GENFIT will unconditionally...

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Written by Customer Service on February 21, 2025. Posted in Public Companies.

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago. Dr. Rubin will provide...

Brunel FY 2024 results: Brunel’s operational agility resulted in strong free cash flow and stable revenue

Written by Customer Service on February 21, 2025. Posted in Earnings Releases And Operating Results.

Amsterdam, 21 February 2025 – Brunel International N.V. (Brunel; BRNL), a global specialist delivering customised project and workforce solutions to drive sustainable industry transformations through technology and talent, today announced its fourth quarter and full year 2024 results. Q4 2024 HighlightsRevenue of EUR 334.5 million, down 3% (down 5% organically) Gross Profit of EUR 61.8 million, down 7% (down 10% organically) Underlying EBIT of EUR 14.4 million, down 2% (down 15% organically) Strong free cash flow of EUR 38.5 million Mr Toine van Doremalen proposed as CFOFY 2024 HighlightsRevenue of EUR 1,364.8 million, up 3% (up 2% organically) Gross Profit of EUR 263.1 million, down 4% (down 5% organically) Underlying EBIT of EUR 58.6 million, down 6% (down 10% organically) Cost reduction plan fully executed in Q3 2024 leading...

NOTICE CONVENING THE ANNUAL GENERAL MEETING OF DFDS A/S

Written by Customer Service on February 21, 2025. Posted in Public Companies.

COMPANY ANNOUNCEMENT no. 09 – 21 February 2025 The annual general meeting of DFDS A/S will be held on Monday 24 March 2025 at 14.30 CET. Please refer to the notice for further information. The notice, including appendix 1 (Candidates for the Board of Directors 2025) and appendix 2 (2025 Remuneration Policy), is attached. Further information is available at: www.dfds.com/en/about/investors/general-meetingsContact Torben Carlsen, CEO +45 33 42 32 01 Karen Boesen, CFO +45 20 58 58 40 Søren Brøndholt Nielsen, IR +45 33 42 33 59 Dennis Kjærsgaard, Media +45 42 30 38 47About DFDS We operate a transport network in and around Europe with an annual revenue of DKK 30bn and 14,000 full-time employees. We move goods in trailers by ferry, road & rail, and we offer complementary and related transport and logistics solutions. We...

NKT A/S Annual Report 2024: 26% organic growth and record-high operational EBITDA

Written by Customer Service on February 21, 2025. Posted in Public Companies.

Company Announcement 21 February 2025Announcement No. 11 NKT A/S Annual Report 2024: 26% organic growth and record-high operational EBITDA NKT CEO Claes Westerlind, on 2024 performance: – 2024 was a pivotal and eventful year for NKT. We continued to deliver on customer commitments, advanced major expansions, launched new investments, and maintained a strong focus on sustainability. These efforts were achieved alongside delivering robust financial performance and further updating our financial ambitions for 2028. With the acquisition of SolidAl and the divestment of NKT Photonics, we took the final steps to transform NKT into a pure-play power cable solutions provider. Financial highlights EURm Q4 2024 Q4 2023 2024 2023Revenue 693* 536* 2,489* 1,927*Organic growth 23% 40% 26% 36%Operational EBITDA 90 63 344 255Operational...

Day: February 21, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals